Overcoming Wnt–β-catenin Dependent Anticancer Therapy Resistance in Leukaemia Stem Cells
John M. Perry,Fang Tao,Anuradha Roy,Tara Lin,Xi C. He,Shiyuan Chen,Xiuling Lu,Jacqelyn Nemechek,Linhao Ruan,Xiazhen Yu,Debra Dukes,Andrea Moran,Jennifer Pace,Kealan Schroeder,Meng Zhao,Aparna Venkatraman,Pengxu Qian,Zhenrui Li,Mark Hembree,Ariel Paulson,Zhiquan He,Dong Xu,Thanh-Huyen Tran,Prashant Deshmukh,Chi Thanh Nguyen,Rajeswari M. Kasi,Robin Ryan,Melinda Broward,Sheng Ding,Erin Guest,Keith August,Alan S. Gamis,Andrew Godwin,G. Sitta Sittampalam,Scott J. Weir,Linheng Li
DOI: https://doi.org/10.1038/s41556-020-0507-y
IF: 21.3
2020-01-01
Nature Cell Biology
Abstract:Leukaemia stem cells (LSCs) underlie cancer therapy resistance but targeting these cells remains difficult. The Wnt-beta-catenin and PI3K-Akt pathways cooperate to promote tumorigenesis and resistance to therapy. In a mouse model in which both pathways are activated in stem and progenitor cells, LSCs expanded under chemotherapy-induced stress. Since Akt can activate beta-catenin, inhibiting this interaction might target therapy-resistant LSCs. High-throughput screening identified doxorubicin (DXR) as an inhibitor of the Akt-beta-catenin interaction at low doses. Here we repurposed DXR as a targeted inhibitor rather than a broadly cytotoxic chemotherapy. Targeted DXR reduced Akt-activated beta-catenin levels in chemoresistant LSCs and reduced LSC tumorigenic activity. Mechanistically, beta-catenin binds multiple immune-checkpoint gene loci, and targeted DXR treatment inhibited expression of multiple immune checkpoints specifically in LSCs, including PD-L1, TIM3 and CD24. Overall, LSCs exhibit distinct properties of immune resistance that are reduced by inhibiting Akt-activated beta-catenin. These findings suggest a strategy for overcoming cancer therapy resistance and immune escape. Targeting resistant stem cells in leukaemia, Perry et al. show that doxorubicin at low doses decreases Akt-mediated beta-catenin activity, downregulates expression of multiple immune-checkpoint genes and dampens tumorigenesis of leukaemia stem cells.